tuberculosis-treatment-market

Tuberculosis Treatment Market By Drug Class (First Line Treatment, Second Line Treatment) - Growth, Share, Opportunities & Competitive Analysis, 2024 - 2032

24 Jul 2017 Format PDF icon PPT icon XLS icon Request Sample

This report on global tuberculosis treatment market studies various drug class. According to World Health Organization (WHO) approximately 49 million lives were saved from 2000-2015 through effective diagnosis and treatment, its end TB strategy aims to eradicate the global TB epidemic with 95% reduction in TB deaths, and to cut new cases by 90% from 2015 to 2035 and to ensure that patients are not burdened with huge expenses incurred due to TB. The drivers of the tuberculosis treatment market are rising prevalence of TB and MDR-TB, increasing public awareness regarding tuberculosis and immediate enrollment of patient on the treatment regimen. Promising pipeline to overcome the drug-induced resistance comprises of Bedaquiline, OPC-67683, PA-824 and OFLOTUB, etc.

For the purpose of this study, the various drug class of tuberculosis treatment studied include first line of treatment which is segmented as Isoniazid, Ethambutol, Pyrazinamide and Rifampin. The second line of treatment comprises of Ethionamide, Cycloserine, Para-amino salicylic acid, and Kanamycin.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global tuberculosis treatment market. Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global tuberculosis treatment market. The key players profiled in this report are Bayer Healthcare, Eli Lilly & Co., Labatec Pharma SA, Macleods Pharmaceuticals Pvt. Ltd., Mylan N.V., Novartis AG, Otsuka Novel Products GmbH, Patheon, Inc., Pfizer, Inc. and Sanofi S.A.

Based on drug class, the global tuberculosis treatment market is categorized into First line treatment Cytochrome P-450 inhibitor (Isoniazid) Mycolic acid inhibitor (Ethambutol) FAS I inhibitor (Pyrazinamide) RNA polymerase inhibitor (Rifampin) Second line treatment Mycolic acid inhibitor (Ethionamide) Peptidoglycans inhibitor (Cycloserine) Folic acid inhibitor (Para-aminosalicylic acid) 30S ribosomal inhibitor (Kanamycin) United Nations in 2015 has adopted the sustainable development goals (SDGs) with one of its major target to eradicate tuberculosis, similarly the World Health Organization is claiming TB strategy class for 90% reduction in tuberculosis deaths and 80% reduction in TB incidence rate by 2030.  Rising public awareness regarding tuberculosis and its treatment regimen, and availability at low cost is fuelling the tuberculosis drug class segment growth. In 2016, first line treatment holds the largest market due to increasing number of new cases of TB, early TB screening resulting into large turnout of patients on first line treatment and government initiatives such as DOTS at the primary health centers to bring under its ambit patients with unmet medical needs. Second line treatment will register faster growth throughout the forecast period 2023-2030, due to factor such as rising prevalence of MDR-TB, according to World Health Organization in 2015 there were 480,000 new reported cases, lack of patient’s compliance to the prescribed first line treatment dosage regimen and rising incidences of hospital acquired infections. Overall, the tuberculosis drug market is highly competitive with presence of multiple players like Novartis AG, Bayer Healthcare, Labatec Pharma SA, Mylan N.V., Otsuka Novel Products GmbH, etc. specializing in respective fields. Consolidation activities are being increasingly witnessed on the competitive front with a view to increase the technological advancement in the drug formulation regarding the pharmacodynamics and pharmacokinetic aspects for better patient compliance and available at low cost.

For the purpose of this study, the global tuberculosis treatment market is categorized into: North America U.S. Canada Europe U.K. Germany Rest of Europe Asia Pacific China Japan Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East and Africa GCC Rest of Middle East and Africa North America will be the fastest growing market for tuberculosis treatment throughout the forecast period 2023-2030. According to the Centers for Disease Control and Prevention 9,421 TB cases were reported in 2014 i.e. rate of 2.96 cases per 100,000 persons, the market growth is mainly attributed to rising prevalence of tuberculosis, evolved reimbursement scenario, and developed healthcare infrastructure. According to the World Health Organization (WHO) in 2015, 32,000 patient’s death were reported in Europe, the tuberculosis treatment market growth is attributed to prevalence of MDR-TB in eastern European countries and supportive regulatory approval for tuberculosis treatment market.

In base year 2021, Asia Pacific was observed as the leading market for tuberculosis treatment due to factors such as rising prevalence of tuberculosis, according to World Health Organization South East Asia has 4.8 million prevalent cases and 450,000 deaths in 2012, competitive market due to manufactures involved in production of tuberculosis treatment drugs, increasing disposable income in these regions and government and non-government initiatives such as DOTS to mitigate tuberculosis. However, factors such as developing health infrastructure, increasing awareness about tuberculosis treatment are going to fuel the rapid growth of tuberculosis treatment market in Latin America and Middle East and Africa region in the near future.   

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Tuberculosis Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Tuberculosis Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

ATTRIBUTE DETAILS
Research Period  2022-2032
Base Year 2023
Forecast Period  2024-2032
Historical Year  2022
Unit  USD Million
Segmentation
Drug Class
  • First line Treatment
    •     Cytochrome P450 inhibitor (Isoniazid)
    •     Mycolic acid inhibitor (Ethambutol)
    •     FAS I inhibitor (Pyrazinamide)
    •     RNA polymerase inhibitor (Rifampin)
  • Second Line Treatment
    •     Mycolic acid inhibitor (Ethionamide)
    •     Peptidoglycans inhibitor (Cycloserine)
    •     Folic acid inhibitor (Para-amino salicylic acid)
    •     30S ribosome inhibitor (Kanamycin)

 Region Segment (2022-2032; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Tuberculosis Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2032.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Tuberculosis Treatment market?
  • Which is the largest regional market for Tuberculosis Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Tuberculosis Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Tuberculosis Treatment market worldwide?
Choose Licence Type
$4325
$6325
$12650
Why Acute
View Other Reports